Media Advisory: ECOG-ACRIN data at ASCO will showcase the Group’s robust research portfolio
An update from the practice-changing DREAMseq (EA6134) trial for melanoma, results of a pancreas cancer trial (E2211), health equity findings, and the latest from the NCI-MATCH precision medicine trial are among a mix of abstracts
Philadelphia, May 17, 2022 — Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present a wide range of abstracts at the annual meeting of the American Society of Clinical Oncology (ASCO), occurring June 3-7 in Chicago and online. The data include evaluations of new approaches to cancer treatment, control, care delivery, and health equity. The National Cancer Institute, part of the National Institutes of Health, funded these studies.
- Updates on Abstract 356154: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134. Author: Michael B. Atkins, MD (Georgetown-Lombardy Comprehensive Cancer Center)
- Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Author: Roxanne Jensen, PhD (National Cancer Institute)
- A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211). Author: Pamela L. Kunz, MD (Yale School of Medicine)
- Association between state Medicaid policies and accrual of Black participants to cancer clinical trials. Author: Samuel U Takvorian, MD, MS (Perelman School of Medicine, University of Pennsylvania)
- Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Author: Ranee Mehra, MD (University of Maryland)
- Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Author: Abhishek Tripathi, MD (University of Oklahoma Health Sciences Center)
- Cluster-randomized trial to evaluate the implementation of reproductive health care in cancer care delivery in community oncology practices: Results from ECOG-ACRIN E1Q11. Author: Ashlesha Patel, MD, MPH (Cook County Health)
- Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. Author: Jennifer R. Eads, MD (University of Pennsylvania, Abramson Cancer Center)
- Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D. Author: Jonathan D. Schoenfeld, MD (Dana-Farber Cancer Institute)
- Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T. Author: Anne S. Tsao, MD (The University of Texas MD Anderson Cancer Center)
- A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. Author: Athanassios Argiris, MD (Thomas Jefferson University)
- Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials. Author: Angela Walter, PhD, MPH, MSW (University of Massachusetts Lowell)
- Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. Author: Fengmin Zhao, PhD (Dana-Farber Cancer Institute—ECOG-ACRIN Biostatistics Center, Boston)
- Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD. Author: Sheetal Mehta Kircher, MD (Northwestern Medicine)
ASCO will release the full abstracts on Thursday, May 26 at 5:00 PM (ET). Abstracts are under the ASCO news embargo until then. To request an interview with one of the authors, send an email to Diane Dragaud, Director of Communications, or call 215-789-3631. Please follow the ASCO 2022 Annual Meeting Media Policies.
###